All AbMole products are for research use only, cannot be used for human consumption.
Orantinib (SU6668; TSU-68) is an oral tyrosine kinase inhibitor of VEGFR-2, PDGFR and FGFR. TSU-68 inhibits SCF-induced proliferation of MO7E cells with IC50 of 0.29 μM, and induces apoptosis. Orantinib (SU6668; TSU-68) also inhibits Aurora kinases B and C (IC50 = 35 and 210 nM respectively). Orantinib (SU6668; TSU-68) suppresses tumor growth, blocks angiogenesis in tumors, and induces apoptosis of tumor vasculature and regression of established tumors. In a tumor model of HT29 human colon carcinoma, Orantinib (200 mg/kg) decreases the average vessel permeability and average fractional plasma volume in the tumor rim and core.
 |
Source | Cell Physiol Biochem (2017). Figure 3. TSU-68 |
| Method | Measurement of VDCC currents | |
| Cell Lines | ASM cells | |
| Concentrations | 100-500 μM | |
| Incubation Time | 30 min | |
| Results | The currents were then removed by 316 μM TSU-68, while 100 μM TSU-68 partially blocked the currents |
| Cell Experiment | |
|---|---|
| Cell lines | HUVECs cells |
| Preparation method | HUVECs (seeded at 2 × 106 cells/10-cm plate) were grown to confluence in endothelial cell growth media [containing 12 μg/ml bovine brain extract, 10 μg/ml human epidermal growth factor, 1 μg/ml hydrocortisone, 2% (v/v) FBS, 50 μg/ml gentamicin, and 50 mg/ml amphotericin B in modified MCDB 131 (Clonetics Corp., Walkersville, MD)] and then quiesced in endothelial cell basal media (modified MCDB 131; Clonetics) containing 0.5% FBS for 24 h before drug treatment. All cell lines were incubated with the indicated concentrations of SU6668 for 60 min before ligand stimulation (100 ng/ml) for 10 min. Preparation of cell lysates, separation of cellular proteins (30 μg from NIH-3T3 engineered cells, 100 μg from HUVECs), and immunoblotting with antiphosphotyrosine antibody were performed as described previously. |
| Concentrations | 0~50 μM |
| Incubation time | 60 min |
| Animal Experiment | |
|---|---|
| Animal models | A375, Calu-6, A431, C6, and SF763T tumor cells xenograft in athymic mice |
| Formulation | DMSO |
| Dosages | 75 or 100 mg/kg |
| Administration | i.p. by bolus injection |
| Molecular Weight | 310.35 |
| Formula | C18H18N2O3 |
| CAS Number | 252916-29-3 |
| Solubility (25°C) | DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| Conbercept
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc. |
| SU5208
SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2). |
| VEGFR-IN-1
VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. |
| (Z)-Orantinib
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. |
| (Rac)-SAR131675
(Rac)-SAR131675 is the racemate of SAR131675. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
